value is an indicative marker for the antagonistic or synergistic effect for the combination effect of two different drugs. The interaction between two drugs was considered synergistic when CI value was lower than 1, additive when equaled 1, and antagonistic when CI was higher than 1.

5

A number of embodiments of the invention have been described. All publications. patents and patent applications citied herein are incorporated herein by reference.

Claims

1. Use of forodesine in combination with rituximab in the manufacture of a medicament for the treatment of hematologic cancer.
2. Use according to claim 1, wherein forodesine and rituximab are to be administered concurrently or sequentially.
3. Use according to either claim 1 or 2, further comprising an alkylating agent.
4. Use according to any one of claims 1 to 3, wherein rituximab is to be administered one or more times prior to administration of forodesine.
5. Use according to claim 3, wherein the alkylating agent is to be administered one or more times prior to the administration of forodesine.
6. Use according to either claim 3 or 5, wherein the alkylating agent is selected from: a mustard derivative, a nitrosourea derivative, a platinum compound, and an imidazole carboxamide compound.
7. Use according to either claim 3 or 5, wherein the alkylating agent is bendamustine.
8. Forodesine in combination with rituximab for use in the treatment of hematologic cancer.
9. Forodesine in combination with rituximab, for use according to claim 8, wherein forodesine and rituximab are to be administered concurrently or sequentially.
10. Forodesine in combination with rituximab, for use according to either claim 8 or 9, further comprising an alkylating agent.
11. Forodesine in combination with rituximab, for use according to any one of claims 8 to 10, wherein rituximab is to be administered one or more times prior to the administration of forodesine.
12. Forodesine in combination with rituximab, for use according to claim 10, wherein the alkylating agent is to be administered one or more times prior to the administration of forodesine.
13. Forodesine in combination with rituximab, for use according to either claim 10 or 12, wherein the alkylating agent is selected from: a mustard derivative, a nitrosourea derivative, a platinum compound, and an imidazole carboxamide compound.
14. Forodesine in combination with rituximab, for use according to either claim 10 or 12, wherein the alkylating agent is bendamustine.

15. Use according to any one of claims 1 to 7 or a combination for use according to any one of claims 8 to 14, wherein the hematologic cancer is selected from chronic lymphocytic leukemia, acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
16. Use according to any one of claims 1 to 7 or a combination for use according to any one of claims 8 to 14, wherein the hematologic cancer is chronic lymphocytic leukemia.
17. A pharmaceutical composition comprising forodesine and rituximab.
18. A pharmaceutical composition according to claim 17, further comprising an alkylating agent.
19. A pharmaceutical composition according to claim 18, wherein the alkylating agent is selected from: a mustard derivative, a nitrosourea derivative, a platinum compound, and an imidazole carboxamide compound.
20. A pharmaceutical composition according to claim 18, wherein the alkylating agent is bendamustine.
21. A kit comprising forodesine and rituximab.
22. A kit according to claim 21, further comprising an alkylating agent.
23. A kit according to claim 22, wherein the alkylating agent is selected from: a mustard derivative, a nitrosourea derivative, a platinum compound, and an imidazole carboxamide compound.
24. A kit according to claim 22, wherein the alkylating agent is bendamustine.
25. A kit according to any one of claims 21 to 24, further comprising a delivery system for forodesine, rituximab, the optional alkylating agent or any combination thereof, said kit optionally further comprising instructions for treating a subject having hematologic cancer.
26. A kit according to claim 25, further comprising instructions for treating a subject having hematologic cancer, wherein the instructions direct the concurrent or sequential administration of forodesine, rituximab and the optional alkylating agent.
27. A kit according to claim 25, further comprising instructions for treating a subject having hematologic cancer, wherein the instructions direct the administration of rituximab, the optional alkylating agent or both rituximab and the optional alkylating agent one or more times prior to the administration of forodesine.

28. A pharmaceutical composition according to any one of claims 17 to 20 or a kit according to any one of claims 21 to 27, wherein the hematologic cancer is selected from chronic lymphocytic leukemia, acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
29. A pharmaceutical composition according to any one of claims 17 to 20 or a kit according to any one of claims 21 to 27, wherein the hematologic cancer is chronic lymphocytic leukemia.